Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients

AIDS

Volumn 12, Issue 11, 1998, Pages

  Mitsuyasu, Ronald T ^a,m   Skolnik, Paul R ^b   Cohen, Stuart R ^c   Conway, Brian ^d   Gill, M John ^e   Jensen, Peter C ^f   Pulvirenti, Joseph J ^g   Slater, Leonard N ^h   Schooleyt, Robert T ⁱ   Thompson, Melanie A ^j   Torres, Ramon A ^k   Tsoukas, Christos M ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Jr Hospital of Cook County   (United States)

^h UNIVERSITY OF OKLAHOMA   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j AIDS Research Consortium of Atlanta   (United States)

^k ST VINCENT S HOSPITAL   (United States)

^l MONTREAL GENERAL HOSPITAL   (Canada)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Combination therapy; HIV 1; Protease inhibitor; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; GELATIN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 7344253584     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00001     Document Type: Article

References (14)

1. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1946, 334:1011-1017.
2. Haubrich R, Burger HU, Beattie D et al.: Saquinavir + zalcitabine versus saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing or intolerant to zidovu~ dine: results of a randomized, double blind trial. AIDS 1996, 10 (suppl 2):OP4,2.
3. Stellbrink H-J for the Invirase International Phase III Trial (SV-14604) Group: Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg, October 1997 [abstract 212].
4. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
5. Buss N, the Fortovase Study Group: Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998, [abstract 354].
6. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
7. Gill MJ, the NV15182 Study Team: Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population [letter]. AIDS 1998, 12:1400-1402.
8. Sension M, Farthing C, Palmer Pattison T, Pilson R, Siemon-Hryczyk P: Fortovase (saquinavir soft gel capsule; SQV-SGC) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients. 5th Conference on Ritroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 369].
9. Opravil M, the Spice Study Team: Study of Protease Inhibitor Combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 394b].
10. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
11. O'Brien TR, Blattner WA, Waters D, et al.: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110.
12. Borletfs JC, the CHEESE Study Team: First comparative study of saquinavir soft gel capsules versus indinavir as part of triple therapy regimen (CHEESE). 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 387b].
13. Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y: Analysis of long-term virologic data from the Viracept (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 372].
14. Mathez D, Bagnarelli P, Gorin I, et al.: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antiviral Ther 1997, 2:75-183.